If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Omvoh ™ (mirikizumab-mrkz) injection
300 mg/15 mL, 100 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Should the dose of Omvoh™ (mirikizumab-mrkz) be adjusted for hepatic function?
No dosing adjustments are needed in patients with hepatic impairment.
Pharmacokinetic Data
Mirikizumab-mrkz is a humanized immunoglobulin G4 (IgG4) monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.1
Specific clinical pharmacology studies to evaluate the effects of hepatic impairment on the pharmacokinetics of mirikizumab have not been conducted.1
Population pharmacokinetic analysis showed that mirikizumab pharmacokinetics were not affected by total bilirubin in the range of 1.5 to 29 µmol/L.1
Enclosed Prescribing Information
Reference
1Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
Date of Last Review: May 30, 2023